RPG Life Sciences Overview
- Founded
-
1968

- Status
-
Public
- Employees
-
1,165

- Stock Symbol
-
RPGLIFE

- Investments
-
1
- Share Price
-
$8.14
- (As of Friday Closing)
RPG Life Sciences General Information
Description
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
Contact Information
Website
www.rpglifesciences.com
Formerly Known As
Searle India
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
NSE
Primary Office
- 463, 4th Floor, RPG HOUSE
- Dr. Annie Besant Road
- Worli, 400030
- India
+91 022 0000 0000
RPG Life Sciences Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$8.14 | $8.32 | $5.82 - $10.22 | $135M | 16.5M | 24.2K | $0.45 |
RPG Life Sciences Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
---|---|---|---|---|
EV | 109,266 | 114,065 | 86,788 | 38,560 |
Revenue | 60,775 | 58,673 | 51,531 | 51,956 |
EBITDA | 12,437 | 11,814 | 9,479 | 7,655 |
Net Income | 7,446 | 6,909 | 5,376 | 4,083 |
Total Assets | 45,446 | 41,308 | 35,366 | |
Total Debt | 0 | 124 | 275 | 1,554 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
RPG Life Sciences Patents
RPG Life Sciences Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9428461-B2 | Process for the preparation of a benzazepine derivative | Expired - Fee Related | 21-Oct-2013 | 0000000000 | |
US-20150112059-A1 | Process for the preparation of a benzazepine derivative | Granted | 21-Oct-2013 | 0000000000 | |
US-8063217-B2 | Process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6, 7-dihydrothieno[3,2-c]pyridine-5(4h) -acetic acid methyl ester or salts thereof having higher chiral purity and products thereof | Expired - Fee Related | 12-Jul-2005 | 0000000000 | |
US-20100004453-A1 | Process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6, 7-dihydrothieno[3,2-c]pyridine-5 (4h) -acetic acid methyl ester or salts thereof having higher chiral purity and products thereof | Granted | 12-Jul-2005 | 0000000000 | |
EP-1902058-A2 | A process for preparation of methyl-(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno(3,2-c)pyridine-5(4h)-acetic acid methyl ester or salts thereof having higher chiral purity and products thereof | Withdrawn | 12-Jul-2005 | C07D495/04 |
RPG Life Sciences Signals
RPG Life Sciences Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000 000000000 | 27-Jul-2016 | 000000000 | 00.000 | Buildings and Property | 00. 00000 |